Clinical Trial

Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets

Study acronym: BAT-VTE
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Venous thromboembolism (VTE) and atherosclerotic cardiovascular disease share common risk factors and frequently coexist in the same patients. Their management requires use of antithrombotic agents: anticoagulant therapy (AC) for secondary prevention of VTE recurrence, antiplatelet (AP) for secondary prevention of major adverse ischemic cardiovascular and cerebrovascular event (MACCE) in patients with atherosclerotic cardiovascular disease (coronary artery disease, atherosclerotic cerebrovascular disease, lower extremity peripheral arterial disease). Side effects of antithrombotic drugs are the 1st cause of emergency admission and hospitalization for an adverse drug reaction (mainly bleeding), and the combination of AC with AP strongly increases this risk.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2022-11-16; most recent amendment 2026-05-05.
Status change: Not Yet Recruiting → Recruiting 2023-10-31
Trial Details
NCT Number NCT05627375
Lead Sponsor Centre Hospitalier Universitaire de Saint Etienne
Collaborators: Ministry of Health, France
Conditions Venous Thromboembolic Disease
Enrollment 1,400 participants
Start Date 2023-08-16
Primary Completion 2027-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-08